Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weighted to the second half
The FTSE 250-listed footwear manufacturer and retailer reported a "positive" performance for its direct-to-consumer business in the Americas, particularly in its shops and full-price sales, though the UK continued to see "a challenging trading backdrop".
In Europe, the Middle East and Africa, trading was mixed, while the Asia Pacific region delivered strong growth, led by South Korea.
The company said its order books for autumn and winter are "healthy" across regions, with EMEA ahead of last year and the Americas broadly flat.
The business remains in the foothills of its Levers for Growth strategy introduced in June with the aim of growing consumer engagement, increasing purchase occasions, optimising distribution, and simplifying operations.
The shares rose 0.9% to 76.8p in early trading on Thursday.